Artificial intelligence

Phone apps not apt for cancerous skin lesion detection and monitoring

February 12, 2020

LONDON – Consumer smartphone apps that use image processing algorithms to assess and monitor potentially cancerous skin lesions have not been properly tested in clinical trials and cannot be relied on to produce accurate results, according to a systematic review of published studies.

MD&M West

Panel dials down the hype around AI to focus on its promise

February 12, 2020

By Meg Bryant

No Comments

ANAHEIM, Calif. – Is artificial intelligence (AI) ready for prime time in health care? What’s hype and what’s real? That’s the question that was posed to an expert panel at MD&M West.

AI partnerships ‘move the industry forward’

Trial recruitment, retention improved but drop-outs persist in late studies

February 11, 2020

By Marie Powers

No Comments

Multiple tactics employed by the biopharma industry to improve the recruitment and retention of participants in clinical trials seem to be paying off. More than three of four (77%) studies now fully enroll on or ahead of schedule, according to researchers at the Tufts Center for the Study of Drug Development (CSDD), reporting in the January/February Tufts CSDD Impact Report on global recruitment performance benchmarks.

French university hospitals grasp AI

January 21, 2020

By Bernard Banga

No Comments

PARIS – EY SAS has published the results of the first edition of a barometer dedicated to the role of artificial intelligence (AI) in French public hospitals. The health care sector, which is undergoing wholesale change in France, is suffering tight economic constraints and faces ever-increasing expectations from patients. “The development of [AI] in France is a priority. It's a matter of gauging it,” Loïc Chabanier, an EY partner responsible for health care, told BioWorld.

Newco news

AI startup Zebiai inks new deals with Google and X-Chem

January 14, 2020

By Lee Landenberger

No Comments

When Zebiai Therapeutics Inc.’s CEO, Rick Wagner, went about naming his new machine learning company, he wanted it to connote something dramatic that displayed the company’s potential to reach into the seemingly boundless future technology had unlocked.

CES Digital Health Summit

Digital health funding landscape still active despite slight dip

January 9, 2020

By Liz Hollis

No Comments

What does the landscape look like in terms of funding for digital health? Geoffrey Starr, a partner at Cooley LLP, dove into this question during the Digital Health Summit, part of CES 2020. He acknowledged that 2019 saw a slight dip in funding compared with the record-breaking previous year. With that said, it was the second largest year ever for digital health care financings, with more than one-third of all health care venture financings involving digital health technologies.

Google Health AI system reduces false mammogram interpretations compared to radiologists

January 3, 2020

By Stacy Lawrence

No Comments

Artificial intelligence (AI) is better than humans at pattern recognition within images and other densely complex datasets. That fact has long been expected to translate into meaningful change in the way we interpret health care data, but beyond a few early exceptions that is not yet the case. Now, the research is starting to amass that demonstrates the real potential for machine learning to significantly improve diagnostics and treatment.

Data rich environment

Artificial intelligence: pushing the boundaries of drug development

December 30, 2019

By Peter Winter

No Comments

The next wave of drug discovery is being enabled by artificial intelligence (AI). This fact has not been lost on investors, who are keeping a close watch on emerging biopharma companies that are using AI and machine learning to enable the discovery of next-generation medicines.

Year in Review: From capital markets to CRISPR, 2019 a pretty good year for biopharma

December 30, 2019

No Comments

For biopharma, 2019 can be described as a terrific year – with a few asterisks. The financial markets were flourishing, with venture capital dollars, in particular, flowing to the sector, while dealmaking reached historic proportions. Meanwhile, scientific breakthroughs led the way as cell and gene therapies gained ground, the first signs of success emerged with new technologies like CRISPR and the long-awaited promise of genomics found its way to the front lines of health care.

'The new gold rush'

AI, machine learning offer hope for speeding Alzheimer’s development

December 16, 2019

By Brian Orelli

No Comments

Machine learning and artificial intelligence (AI) are already being actively used in drug discovery to evaluate potential binding of small-molecule drugs to proteins, but there's potential for the technologies to be used on the development side as well, especially in hard-to-treat diseases such as Alzheimer's disease.